Literature DB >> 27916675

Shifting from tuberculosis control to elimination: Where are we? What are the variables and limitations? Is it achievable?

Rosella Centis1, Lia D'Ambrosio2, Alimuddin Zumla3, Giovanni Battista Migliori4.   

Abstract

Tuberculosis (TB) is a priority in terms of incidence and mortality, with about 10.4 million new incident cases and 1.8 million deaths in 2015. The End-TB strategy recently launched by the World Health Organization in the context of the post-2015 agenda, aimed to achieve TB elimination, represents an evolution of the previous historical strategies originally aimed to achieve TB control. Globally, the current decline in TB incidence is rather slow at approximately 1,5% per year to reach the TB pre-elimination phase by 2035 (A more aggressive approach based on diagnosis and treatment of latently infected individuals has been proposed in the context of TB elimination to ensure future generations free of TB. We describes 4 scenarios which, combined, describe the TB epidemiology in a given setting: 1) in absence of interventions, 2) with early TB diagnosis and effective treatment, 3) with irregular TB treatment, 4) with TB co-infected by HIV not undergoing anti-retroviral treatment. To achieve TB Elimination, a more concerted action by funders and governments will be required for further investments into TB prevention, detection and treatment.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Elimination; LTBI; MDR-TB; Strategy; Tuberculosis

Mesh:

Substances:

Year:  2016        PMID: 27916675     DOI: 10.1016/j.ijid.2016.11.416

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  9 in total

1.  Designing of phenol-based β-carbonic anhydrase1 inhibitors through QSAR, molecular docking, and MD simulation approach.

Authors:  Shahzaib Ahamad; Md Imtaiyaz Hassan; Neeraja Dwivedi
Journal:  3 Biotech       Date:  2018-05-14       Impact factor: 2.406

2.  In vitro analysis of antigen induced T cell-monocyte conjugates by imaging flow cytometry.

Authors:  Meseret Habtamu; Markos Abebe; Abraham Aseffa; Anne Margarita Dyrhol-Riise; Anne Spurkland; Greger Abrahamsen
Journal:  J Immunol Methods       Date:  2018-07-04       Impact factor: 2.303

3.  Challenges in urogenital tuberculosis.

Authors:  Ekaterina Kulchavenya; Denis Kholtobin; Sergey Shevchenko
Journal:  World J Urol       Date:  2019-04-17       Impact factor: 4.226

Review 4.  Adapting Clofazimine for Treatment of Cutaneous Tuberculosis by Using Self-Double-Emulsifying Drug Delivery Systems.

Authors:  Daniélle van Staden; Richard K Haynes; Joe M Viljoen
Journal:  Antibiotics (Basel)       Date:  2022-06-15

5.  Expression of mycobacterium tuberculosis induced SOCS3 and STAT3 and the implications on innate immunity in TB patients vs healthy contacts in high TB/HIV endemic setting: A cross-sectional analytical study.

Authors:  Patrick Lungu; Kabaso Mushota; Evarist Njelesani; Thomas Sukwa; Shabir Lakhi; Peter Mwaba
Journal:  PLoS One       Date:  2022-07-15       Impact factor: 3.752

Review 6.  Setting targets for HIV/AIDS-What lessons can be learned from other disease control programmes?

Authors:  Tazeem Bhatia; Jamie Enoch; Mishal Khan; Sophie Mathewson; David Heymann; Richard Hayes; Osman Dar
Journal:  PLoS Med       Date:  2019-02-04       Impact factor: 11.069

7.  Cold abscess as a primary manifestation of thyroid tuberculosis.

Authors:  Sumadi Lukman Anwar; Artanto Wahyono; Ery Kus Dwianingsih; Widya Surya Avanti
Journal:  IDCases       Date:  2022-06-20

8.  HupB Is a Bacterial Nucleoid-Associated Protein with an Indispensable Eukaryotic-Like Tail.

Authors:  Joanna Hołówka; Damian Trojanowski; Katarzyna Ginda; Bartosz Wojtaś; Bartłomiej Gielniewski; Dagmara Jakimowicz; Jolanta Zakrzewska-Czerwińska
Journal:  MBio       Date:  2017-11-07       Impact factor: 7.867

9.  Increased Neutrophil Count and Decreased Neutrophil CD15 Expression Correlate With TB Disease Severity and Treatment Response Irrespective of HIV Co-infection.

Authors:  Lerato N Ndlovu; Lauren Peetluk; Sashen Moodley; Shepherd Nhamoyebonde; Abigail T Ngoepe; Matilda Mazibuko; Khadija Khan; Farina Karim; Alexander S Pym; Fernanda Maruri; Mahomed-Yunus S Moosa; Yuri F van der Heijden; Timothy R Sterling; Alasdair Leslie
Journal:  Front Immunol       Date:  2020-08-28       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.